Champion Chatter – what costs more than £500,000 per gram?
UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics
Mkt cap £154n – shares down 6% on the day
Audited (not preliminary) results for the year ended 30 June 2018.
Congratulations to Bioventix for the timely reporting of their audited financial statements.
The highlights make great reading:
Revenue up 21% to £8.8m - revenue benefitted from a…
Sign up and read the full article
Register to continue reading our content.
Already a member? Login
Previous article Next article